These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26626205)

  • 1. Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
    Mele G; Coppi MR; Guaragna G; Spina A; Melpignano A
    Leuk Res; 2016 Jan; 40():30-2. PubMed ID: 26626205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.
    Wöhrer S; Ackermann J; Baldia C; Seidl S; Raderer M; Simonitsch I; Drach J
    Hematol J; 2004; 5(4):361-3. PubMed ID: 15297854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma cell leukaemia].
    Rodriguez C; Pont JC; Gouin-Thibault I; Andrieu AG; Molina T; Le Tourneau A; Le Garff-Tavernier M; Siguret V; Chaibi P
    Ann Biol Clin (Paris); 2005; 63(5):535-9. PubMed ID: 16230292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M
    Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
    Musto P; Simeon V; Martorelli MC; Petrucci MT; Cascavilla N; Di Raimondo F; Caravita T; Morabito F; Offidani M; Olivieri A; Benevolo G; Mina R; Guariglia R; D'Arena G; Mansueto G; Filardi N; Nobile F; Levi A; Falcone A; Cavalli M; Pietrantuono G; Villani O; Bringhen S; Omedè P; Lerose R; Agnelli L; Todoerti K; Neri A; Boccadoro M; Palumbo A
    Leukemia; 2014 Jan; 28(1):222-5. PubMed ID: 23958922
    [No Abstract]   [Full Text] [Related]  

  • 6. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
    Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
    Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
    Musto P; Pietrantuono G; Guariglia R; Villani O; Martorelli MC; D'Auria F; Zonno A; Lerose R
    Leuk Res; 2008 Oct; 32(10):1637-8. PubMed ID: 18433866
    [No Abstract]   [Full Text] [Related]  

  • 11. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
    Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
    Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide.
    Engelhardt M; Wäsch R; Reinhardt H; Kleber M
    Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
    Brück P; Mousset S; Bühme A; Hoelzer D; Atta J
    Int J Hematol; 2007 Jul; 86(1):66-8. PubMed ID: 17675269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New graphic AUC-based method to estimate overall survival benefit: pomalidomide reanalysis.
    Fenix-Caballero S; Diaz-Navarro J; Prieto-Callejero B; Rios-Sanchez E; Alegre-del Rey EJ; Borrero-Rubio JM
    J Clin Pharm Ther; 2016 Feb; 41(1):1-3. PubMed ID: 26667205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
    Pretz J; Medeiros BC
    Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.